BRPI0408518A - combination therapy comprising nemorubicin and a cyclooxygenase-2 inhibitor - Google Patents

combination therapy comprising nemorubicin and a cyclooxygenase-2 inhibitor

Info

Publication number
BRPI0408518A
BRPI0408518A BRPI0408518-3A BRPI0408518A BRPI0408518A BR PI0408518 A BRPI0408518 A BR PI0408518A BR PI0408518 A BRPI0408518 A BR PI0408518A BR PI0408518 A BRPI0408518 A BR PI0408518A
Authority
BR
Brazil
Prior art keywords
inhibitor
nemorubicin
cyclooxygenase
combination therapy
cox
Prior art date
Application number
BRPI0408518-3A
Other languages
Portuguese (pt)
Inventor
Maria Cristina Geroni
Maria Adele Pacciarini
Antonino Suarato
Original Assignee
Pharmacia Italia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia Spa filed Critical Pharmacia Italia Spa
Publication of BRPI0408518A publication Critical patent/BRPI0408518A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"TERAPIA COMBINADA COMPREENDENDO NEMORUBICIN E UM INIBIDOR DE CICLOOXIGENASE-2". A presente invenção refere-se ao uso de um derivado de morfolinil antraciclina, um sal farmaceuticamente aceitável ou metabólito do mesmo, para a preparação de um medicamento em combinação com um inibidor de Cox-2, para uso simultâneo, separado ou seqüencial em tratamento de câncer, e a composições ou unidades embaladas compreendendo um derivado de morfolinil antraciclina e um inibidor de Cox-2."COMBINED THERAPY UNDERSTANDING NEMORUBICIN AND A CYCLOOXYGENASE-2 INHIBITOR". The present invention relates to the use of a morpholinyl anthracycline derivative, a pharmaceutically acceptable salt or metabolite thereof, for the preparation of a medicament in combination with a Cox-2 inhibitor for simultaneous, separate or sequential use in the treatment of cancer, and packaged compositions or units comprising a morpholinyl anthracycline derivative and a Cox-2 inhibitor.

BRPI0408518-3A 2003-03-18 2004-03-04 combination therapy comprising nemorubicin and a cyclooxygenase-2 inhibitor BRPI0408518A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03075780 2003-03-18
PCT/EP2004/050251 WO2004082689A1 (en) 2003-03-18 2004-03-04 Combined therapy comprising nemorubicin and a cyclooxygenase-2-inhibitor

Publications (1)

Publication Number Publication Date
BRPI0408518A true BRPI0408518A (en) 2006-03-07

Family

ID=33016930

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0408518-3A BRPI0408518A (en) 2003-03-18 2004-03-04 combination therapy comprising nemorubicin and a cyclooxygenase-2 inhibitor

Country Status (6)

Country Link
EP (1) EP1605951A1 (en)
AU (1) AU2004222527A1 (en)
BR (1) BRPI0408518A (en)
CA (1) CA2519310A1 (en)
MX (1) MXPA05009849A (en)
WO (1) WO2004082689A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009099741A1 (en) 2008-02-01 2009-08-13 Genentech, Inc. Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods
CN101555264B (en) * 2008-04-11 2014-09-03 天津和美生物技术有限公司 Derivative of highly active tetra cyclic anthroquinones antibiotics and preparation and application thereof
JP5647971B2 (en) 2008-04-11 2015-01-07 天津和美生物技▲術▼有限公司Ｔｉａｎｊｉｎ Ｈｅｍａｙ Ｂｉｏ−Ｔｅｃｈ Ｃｏ．Ｌｔｄ Derivatives of highly active anthracycline antibiotics, production and application of the derivatives
BRPI0910810A2 (en) 2008-07-15 2019-09-24 Genentech Inc anthracycline derivative conjugates, polymeric carrier, antibody, peptide or protein, t- [cho] m carrier, pharmaceutical compositions, methods of treating cancer or cell proliferation disorders, anthracycline derivative, drug-antibody conjugate compound, use, article of Manufacture and Method of Production of a Drug-Antibody Conjugate Compound "
RU2563638C2 (en) 2010-12-02 2015-09-20 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Method of obtaining morpholinylanthracycline derivatives
CN106714844B (en) 2014-09-12 2022-08-05 基因泰克公司 Anthracycline disulfide intermediates, antibody-drug conjugates and methods
US10328159B2 (en) * 2014-10-03 2019-06-25 Engenic Molecular Delivery Pty Ltd. Enhanced loading of intact, bacterially derived vesicles with small molecule compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2094136T3 (en) * 1989-12-19 1997-01-16 Pharmacia Spa CHIRAL INTERMEDIARIES OF 1,5-DIYODO-2-METOXI OR BENCILOXI.
GB2296495B (en) * 1994-12-23 1998-04-15 Erba Carlo Spa Anthracycline derivatives
AU2593600A (en) * 1998-12-23 2000-07-12 G.D. Searle & Co. Method of using a cyclooxygenase-2 inhibitor and a matrix metalloproteinase inhibitor as a combination therapy in the treatment of neoplasia
GB9909925D0 (en) * 1999-04-29 1999-06-30 Pharmacia & Upjohn Spa Combined preparations comprising anthracycline derivatives

Also Published As

Publication number Publication date
AU2004222527A1 (en) 2004-09-30
WO2004082689A1 (en) 2004-09-30
EP1605951A1 (en) 2005-12-21
CA2519310A1 (en) 2004-09-30
MXPA05009849A (en) 2005-12-06

Similar Documents

Publication Publication Date Title
BRPI0415007A (en) method for treating, preventing, modifying or administering pain and pharmaceutical composition
WO2006050155A3 (en) Cancer therapeutic compositions
BRPI0410503B8 (en) topical composition and use of composition
BRPI0418029A (en) cd40 antibody formulation and methods
BRPI0612845A8 (en) compound, pharmaceutical formulation, methods for treating cancer and for synthesizing a compound of formula
BRPI0407897A (en) cyanopyridine derivatives useful in the treatment of cancer and other disorders
BRPI0416260A (en) method for treating, preventing or controlling an asbestos-related disease or disorder and pharmaceutical composition
AR034900A1 (en) USE OF AN EFFECTIVE AMOUNT OF A PDE4 INHIBITOR AND AN ANTI-POLINERGIC AGENT, WELL IN COMBINED FORM ONLY OR SEPARATELY, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM, METHOD TO PREPARE THEM, AND USE OF A COMPOSITION THAT INCLUDES AN EFFECTIVE AMOUNT OF A PDD AN EFFECTIVE AMOUNT
CO5640094A2 (en) A PHARMACEUTICAL COMPOSITION INCLUDING A P2X7 RECEIVER ANTAGONIST AND AN ALPHUS TUMOR NECROSIS FACTOR
DK1827500T3 (en) Pegylated liposomal doxorubicin in combination with ecteinescidin 743
BRPI0407234A (en) Substituted heterocycles
BRPI0413974A (en) combination, method of treating cancer in a warm-blooded animal, pharmaceutical composition, and, use of a combination
MX2009011900A (en) Diabetic wound healing.
AR031761A1 (en) REPINOTANE KIT
BR0313413A (en) Use of beta amyloid vaccination together with a selective cox-2 inhibitor for the treatment of alzheimer's disease
BRPI0408518A (en) combination therapy comprising nemorubicin and a cyclooxygenase-2 inhibitor
AR036321A1 (en) METHOD AND PHARMACEUTICAL FORMULATION FOR THE TREATMENT OF LATE APPEARANCE DYSCINESIA.
BR0206819A (en) Use of il-18 inhibitors for treatment and / or prevention of heart disease.
BRPI0408944A (en) method for providing a steroid reducing benefit with a cyclooxygenase-2 inhibitor and compositions with this
WO2004100893A3 (en) Methods for treatment of inflammatory diseases using ct-3 or analogs thereof
GB0507598D0 (en) Composition
PT1220676E (en) PREVENTION OF COLORCECTAL CANCER
BRPI0415651A (en) methods for treating, preventing, modifying and / or administering fibromyalgia, and for reducing or preventing an adverse effect associated with the administration of a second active ingredient in a fibromyalgia patient, and, pharmaceutical composition.
BRPI0416266A (en) method for treating, preventing and / or controlling an asbestos-related disease or disorder in a patient
O'Steen et al. Venetoclax synergizes with radiation therapy for treatment of B-cell lymphomas

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]